Payload Information

General Information of This Payload
Payload ID
PAY0VZNCV
Name
HDP 30.2115
Synonyms
HDP 30.2115
   Click to Show/Hide
Target(s) DNA-directed RNA polymerase II subunit RPB2 (POLR2B); DNA-directed RNA polymerase III subunit RPC7 (POLR3G)
 Target Info 
Structure
Formula
C40H58N10O11S
Isosmiles
CCC(C)C1NC(=O)CNCC2Cc3c([nH]c4ccccc34)SCC(NC(=O)CNCC1=O)C(=O)NC(CC(N)=O)C(=O)N1CC(O)CC1C(=O)NC(C(C)C(O)CO)C(=O)N2
InChI
InChI=1S/C40H58N10O11S/c1-4-19(2)34-29(53)13-43-14-32(56)45-27-18-62-39-24(23-7-5-6-8-25(23)47-39)9-21(12-42-15-33(57)48-34)44-38(60)35(20(3)30(54)17-51)49-37(59)28-10-22(52)16-50(28)40(61)26(11-31(41)55)46-36(27)58/h5-8,19-22,26-28,30,34-35,42-43,47,51-52,54H,4,9-18H2,1-3H3,(H2,41,55)(H,44,60)(H,45,56)(H,46,58)(H,48,57)(H,49,59)
InChIKey
JRGTXZHGUBMBQP-UHFFFAOYSA-N
Pharmaceutical Properties
Molecule Weight
887.03
Polar area
326.51
Complexity
62
xlogp Value
-4.1254
Heavy Count
62
Rot Bonds
7
Hbond acc
14
Hbond Donor
12
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
HDP-101 [Phase 2]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 11 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.01 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma U266B1 cells CVCL_0566
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.04 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.16 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma MM1.S cells CVCL_8792
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.18 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma INA-6 cells CVCL_5209
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.30 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma LP-1 cells CVCL_0012
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.34 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Multiple myeloma SK-MM-1 cells CVCL_A478
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
4.83 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma L-363 cells CVCL_1357
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
34.20 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma OPM-2 cells CVCL_1625
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
142.00 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Plasma cell myeloma RPMI-8226 cells CVCL_0014
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000.00 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Normal HS-5 cells CVCL_3720
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 1000.00 nM
Method Description
The inhibitory activity of HDP-101 against cancer cell growth was evaluated in various human cancer cell lines in vitro. The cells were treated 2 or 4 days.
In Vitro Model Osteosarcoma U2OS cells CVCL_0042
References
Ref 1 HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells. Mol Cancer Ther. 2021 Feb;20(2):367-378.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.